Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Acquir Immune Defic Syndr ; 21(4): 301-6, 1999 Aug 01.
Article in English | MEDLINE | ID: mdl-10428108

ABSTRACT

The efficacy and toxicity of foscarnet cream for the treatment of mucocutaneous herpes simplex virus lesions or lesions that were clinically unresponsive to systemic acyclovir treatment (median, 30.5 days) in AIDS patients were studied in a phase I/II, open-label, nonrandomized multicenter trial. In the study, 20 patients with advanced stages of AIDS were treated with foscarnet 1% cream five times a day for a mean duration of 34.5 days. Response of index lesions (n = 20) was judged to be completely healed (8 lesions), excellent (4 lesions), or good (1 lesion) in 65% of lesions. The median time to first negative herpes simplex virus culture of index lesion was 8 days. Among 15 patients with pain at baseline, 11 had complete resolution of pain and 2 had at least a 50% reduction. Clinical adverse events included skin ulceration (4 patients), application site reactions (3 patients), fever (3 patients), and headache (3 patients). Five (25%) patients developed new lesions due to herpes simplex virus at sites other than those being treated topically while enrolled in the study. Topical foscarnet 1% cream appears to be a safe and effective treatment for acyclovir-unresponsive mucocutaneous herpes simplex virus infection in AIDS patients.


Subject(s)
AIDS-Related Opportunistic Infections/drug therapy , Antiviral Agents/administration & dosage , Foscarnet/administration & dosage , Herpes Simplex/complications , Herpes Simplex/drug therapy , Acyclovir/therapeutic use , Administration, Topical , Adult , Antiviral Agents/adverse effects , Drug Eruptions/etiology , Drug Resistance, Microbial , Female , Foscarnet/adverse effects , Humans , Male , Middle Aged , Safety , Skin Ulcer/chemically induced
2.
Int Clin Psychopharmacol ; 14(2): 101-12, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10220125

ABSTRACT

The primary objective of this study was to evaluate the efficacy, safety and tolerability of remoxipride (controlled release) versus haloperidol in patients with negative symptoms. The study comprised a multicentre, randomised, double-blind, parallel-group clinical trial. Two hundred and five patients were randomised to either remoxipride or haloperidol. Patients eligible for this study were aged 18-65 years, met the DSM-III-R diagnosis for chronic schizophrenia and the Positive and Negative Symptoms Scale (PANSS) criteria for predominant negative symptoms. There was a statistically significant reduction in the PANSS scores of at least 20% from baseline to last rating for 39 remoxipride (49.4%) and 45 haloperidol (47.6%) treated patients. There were no statistical differences found between the two treatment groups with respect to improvement of negative symptoms and adverse events. The PANSS data suggest that both remoxipride and haloperidol improve the cluster of negative symptoms concerned with social functioning. In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia.


Subject(s)
Haloperidol/therapeutic use , Remoxipride/therapeutic use , Schizophrenia/drug therapy , Schizophrenic Psychology , Adult , Delayed-Action Preparations/adverse effects , Delayed-Action Preparations/therapeutic use , Double-Blind Method , Female , Haloperidol/adverse effects , Humans , Male , Psychiatric Status Rating Scales , Remoxipride/adverse effects
3.
Antimicrob Agents Chemother ; 41(9): 1961-4, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9303394

ABSTRACT

A topical 3% foscarnet cream formulation was evaluated for its ability to treat experimental UV radiation (UVR)-induced herpes labialis in a double-blind study. Healthy adult volunteers with a history of sunlight-induced herpes labialis were randomly assigned at four centers to receive either foscarnet cream (n = 152) or a vehicle control (n = 150). Following measurement of the minimal erythematous dose (MED), the subjects' lips were exposed to 4 MEDs of UV light. Subjects applied the cream on the UVR-exposed area approximately eight times daily beginning immediately after UVR exposure and continuing for 7 days, or until all lesions had a minimum of 4 days of treatment. There were no significant differences between groups in the percentages of subjects that developed any lesion, aborted lesions (did not progress beyond a papule), immediate lesions (developed within 48 h of UVR), or delayed classic lesions (developed 48 h to 7 days after UVR). Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78). There was also a trend for a decrease in the mean duration of these lesions (156 versus 191 h; P = 0.08) and the duration of pain (3.9 versus 4.3 days; P = 0.06) in foscarnet-treated subjects. There were no clinically significant adverse reactions. These data suggest that topical foscarnet can be efficacious and deserves further evaluation for the treatment of herpes labialis.


Subject(s)
Antiviral Agents/administration & dosage , Foscarnet/administration & dosage , Herpes Labialis/drug therapy , Herpes Labialis/etiology , Simplexvirus , Ultraviolet Rays/adverse effects , Adolescent , Adult , Aged , Double-Blind Method , Female , Humans , Male , Middle Aged , Ointments , Sunlight/adverse effects
4.
Acta Derm Venereol ; 70(2): 132-6, 1990.
Article in English | MEDLINE | ID: mdl-1969197

ABSTRACT

The analgesic effect of EMLA 5% cream for surgical cleansing of leg ulcers was investigated in an open study and in a double-blind comparison with placebo. Eighty patients with ulcers of venous or arterial origin participated. The cream was applied under occlusion and removed before cleansing. Plasma concentrations of lidocaine and prilocaine were assessed. The maximum individual concentrations were 0.8 microgram/ml for lidocaine and 0.08 microgram/ml for prilocaine. Pain was assessed according to a verbal rating scale and on a 100 mm visual analogue scale. The median VAS pain scores for EMLA and placebo were 18.5 and 84 mm (p less than 0.01). There were no severe adverse reactions. The results show that there is a need for pain control in surgical debridement of leg ulcers and that EMLA cream gives satisfactory analgesia for this procedure.


Subject(s)
Anesthetics, Local , Debridement/methods , Leg Ulcer/surgery , Lidocaine , Pain/prevention & control , Prilocaine , Administration, Topical , Adult , Aged , Aged, 80 and over , Double-Blind Method , Drug Combinations , Female , Humans , Leg Ulcer/physiopathology , Lidocaine, Prilocaine Drug Combination , Male , Middle Aged , Pain/physiopathology , Pain Measurement/methods , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...